RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SAB Biotherapeutics Stock

SAB Biotherapeutics Debt 2024

SAB Biotherapeutics Debt

-51.97 USD

Ticker

SABS

ISIN

US78397T1034

In 2024, SAB Biotherapeutics's total debt was -51.97 USD, a 421.21% change from the -9.97 USD total debt recorded in the previous year.

SAB Biotherapeutics Aktienanalyse

What does SAB Biotherapeutics do?

SAB Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding SAB Biotherapeutics's Debt Structure

SAB Biotherapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing SAB Biotherapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to SAB Biotherapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in SAB Biotherapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about SAB Biotherapeutics stock

What is the debt of SAB Biotherapeutics this year?

SAB Biotherapeutics has a debt level of -51.97 USD this year.

What was the debt of SAB Biotherapeutics compared to the previous year?

The debt of SAB Biotherapeutics has increased by 421.21% compared to the previous year increased.

What are the consequences of high debt for investors in SAB Biotherapeutics?

High debt can pose a risk for investors of SAB Biotherapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of SAB Biotherapeutics?

Low debt means that SAB Biotherapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from SAB Biotherapeutics affect the company?

An increase in debt of SAB Biotherapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of SAB Biotherapeutics affect the company?

A reduction in debt of SAB Biotherapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of SAB Biotherapeutics?

Some factors that can influence the debt of SAB Biotherapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of SAB Biotherapeutics so important for investors?

The debts of SAB Biotherapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can SAB Biotherapeutics take to change the debt?

To change the debt, SAB Biotherapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does SAB Biotherapeutics pay?

Over the past 12 months, SAB Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SAB Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SAB Biotherapeutics?

The current dividend yield of SAB Biotherapeutics is .

When does SAB Biotherapeutics pay dividends?

SAB Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SAB Biotherapeutics?

SAB Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of SAB Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SAB Biotherapeutics located?

SAB Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SAB Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SAB Biotherapeutics from 11/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/15/2024.

When did SAB Biotherapeutics pay the last dividend?

The last dividend was paid out on 11/15/2024.

What was the dividend of SAB Biotherapeutics in the year 2023?

In the year 2023, SAB Biotherapeutics distributed 0 USD as dividends.

In which currency does SAB Biotherapeutics pay out the dividend?

The dividends of SAB Biotherapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SAB Biotherapeutics

Our stock analysis for SAB Biotherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SAB Biotherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.